Tandem Diabetes Care Inc. (NASDAQ:TNDM) – B. Riley issued their Q3 2016 earnings per share estimates for Tandem Diabetes Care in a report issued on Tuesday. B. Riley analyst G. Chodaczek anticipates that the firm will earn ($0.60) per share for the quarter. B. Riley currently has a “Buy” rating and a $10.00 price objective on the stock. B. Riley also issued estimates for Tandem Diabetes Care’s Q4 2016 earnings at ($0.34) EPS, FY2016 earnings at ($2.21) EPS, Q1 2017 earnings at ($0.55) EPS, Q2 2017 earnings at ($0.54) EPS, Q3 2017 earnings at ($0.49) EPS, Q4 2017 earnings at ($0.22) EPS and FY2017 earnings at ($1.81) EPS.
A number of other analysts have also recently issued reports on the company. Zacks Investment Research upgraded Tandem Diabetes Care from a “hold” rating to a “buy” rating and set a $9.00 price objective on the stock in a research report on Thursday. Wedbush reaffirmed an “outperform” rating and issued a $20.00 price target on shares of Tandem Diabetes Care in a research note on Friday, July 29th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $13.71.
Tandem Diabetes Care (NASDAQ:TNDM) opened at 7.66 on Thursday. The stock’s market capitalization is $234.50 million. The stock’s 50 day moving average price is $7.26 and its 200 day moving average price is $7.80. Tandem Diabetes Care has a 1-year low of $6.04 and a 1-year high of $12.48.
Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Thursday, July 28th. The medical device company reported ($0.60) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.65) by $0.05. The company earned $23 million during the quarter, compared to analysts’ expectations of $23.08 million. Tandem Diabetes Care had a negative return on equity of 132.55% and a negative net margin of 80.21%. The business’s revenue was up 46.5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.65) EPS.
In other Tandem Diabetes Care news, EVP John F. Sheridan sold 15,000 shares of the business’s stock in a transaction on Monday, August 1st. The stock was sold at an average price of $6.52, for a total value of $97,800.00. Following the transaction, the executive vice president now owns 22,763 shares of the company’s stock, valued at $148,414.76. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 37.10% of the stock is owned by corporate insiders.
Institutional investors have recently bought and sold shares of the company. Quantitative Systematic Strategies LLC raised its position in Tandem Diabetes Care by 41.9% in the second quarter. Quantitative Systematic Strategies LLC now owns 14,691 shares of the medical device company’s stock worth $108,000 after buying an additional 4,335 shares in the last quarter. A.R.T. Advisors LLC acquired a new position in Tandem Diabetes Care during the second quarter worth approximately $108,000. Alliancebernstein L.P. acquired a new position in Tandem Diabetes Care during the second quarter worth approximately $112,000. Royal Bank of Canada raised its position in Tandem Diabetes Care by 48.3% in the first quarter. Royal Bank of Canada now owns 13,959 shares of the medical device company’s stock worth $122,000 after buying an additional 4,544 shares in the last quarter. Finally, Rhumbline Advisers raised its position in Tandem Diabetes Care by 3.8% in the second quarter. Rhumbline Advisers now owns 16,317 shares of the medical device company’s stock worth $123,000 after buying an additional 600 shares in the last quarter. 58.85% of the stock is currently owned by institutional investors.
About Tandem Diabetes Care
Tandem Diabetes Care, Inc is a medical device company. The Company is engaged in designing, developing and commercializing products for people with insulin-dependent diabetes. The Company manufactures and sells three insulin pump products, which include t:slim Insulin Delivery System (t:slim), t:flex Insulin Delivery System (t:flex) and t:slim G4 Insulin Delivery System (t:slim G4).
Receive News & Ratings for Tandem Diabetes Care Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care Inc. and related companies with MarketBeat.com's FREE daily email newsletter.